- Characteristics of included patients. N= 44 patients.
| Characteristics | n (%) |
|---|---|
| Age | |
| <6 years old | 9 (20.5) |
| 6–11 years old | 24 (54.5) |
| >11 years old | 11 (25) |
| Sex | |
| Male | 31 (70.5) |
| Female | 13 (29.5) |
| Age at first seizure onset | |
| 0–3 months | 10 (22.7) |
| 4–8 months | 31 (70.5) |
| >1 year | 3 (6.8) |
| Type of seizure | |
| Generalized convulsive seizure | 20 (45.5) |
| Generalized convulsive seizure + focal seizures | 11 (25) |
| Generalized convulsive seizure +Atypical absence seizure | 7 (15.9) |
| Generalized convulsive seizure + focal seizures+Atypical absence seizure | 6 (13.6) |
| Current developmental status | 6 (13.6) |
| Global developmental delay (patients below the age of 5 years) | 28 (63.6) |
| Intellectual disability (patients above the age of 5 years) | 6 (13.6) |
| Speech delay | 3 (6.8) |
| Cognitive delay | 1 (2.4) |
| Family history of epilepsy | |
| Yes | 8 (18.2) |
| No | 36 (81.8) |
| Concomitant Anti-seizure medications | |
| Valproic acid | 29 (65.9) |
| Clobazam | 33 (75) |
| Levetiracetam | 10 (22.7) |
| Phenobarbitone | 3 (6.8) |
| Topiramate | 4 (9.1) |
| Cannabidiol | 1 (2.4) |
| Rufinamide | 1 (2.4) |
| Clonazepam | 3 (6.8) |
| List of failed Anti-seizure therapies | |
| Levetiracetam | 24 (54.5) |
| Lacosamide | 2 (4.5) |
| Clobazam | 5 (11.4) |
| Topiramate | 22 (50) |
| Lamotrigine | 7 (15.9) |
| Carbamazepine | 10 (22.7) |
| Rufinamide | 3 (6.8) |
| Phenytoin | 2 (4.5) |
| Clonazepam | 5 (11.4) |
| Ketogenic diet | 3 (6.8) |
| Zonisamide | 2 (4.5) |
| Cannabidol | 1 (2.4) |